Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.

The off-target distribution of anticancer nanoparticles to fibroblasts creates a barrier to the effective treatment of desmoplastic tumors. However, we hypothesized that this nanoparticle detriment might be exploited to target the expression of secreted cytotoxic proteins from tumor-associated fibroblasts (TAF) as an anticancer strategy. In addressing this hypothesis, plasmids encoding the secretable TNF-related factor sTRAIL were loaded into lipid-coated protamine DNA complexes and administered by infusion in a murine xenograft model of human desmoplastic bladder carcinoma. Three doses were sufficient to generate approximately 70% of TAFs as sTRAIL-producing cells. sTRAIL triggered apoptosis in tumor cell nests adjacent to TAFs. Furthermore, it reverted residual fibroblasts to a quiescent state due to insufficient activation, further compromising tumor growth and remodeling the microenvironment to favor second-wave nanotherapy. We confirmed the efficacy of this strategy in an orthotopic xenograft model of human pancreatic cancer, where the desmoplastic stroma is well known to be a major barrier to the delivery of therapeutic nanoparticles. Collectively, our results offer a proof of concept for the use of nanoparticles to modify TAFs as an effective strategy to treat desmoplastic cancers. Cancer Res; 77(3); 719-31. ©2016 AACR.

[1]  J. DeSimone,et al.  Subtumoral analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle properties. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[2]  W. Quax,et al.  Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity , 2016, Oncogene.

[3]  M. Detmar,et al.  Findings questioning the involvement of Sigma-1 receptor in the uptake of anisamide-decorated particles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Leaf Huang,et al.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Jain,et al.  Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages , 2015, PloS one.

[6]  William Y. Kim,et al.  Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Ralph Weissleder,et al.  Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.

[8]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[9]  O. De Wever,et al.  Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics , 2015, Virchows Archiv.

[10]  D. Hedley,et al.  Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[11]  David M. Kaetzel,et al.  Metastasis suppressor NME1 regulates melanoma cell morphology, self‐adhesion and motility via induction of fibronectin expression , 2015, Experimental dermatology.

[12]  William Y. Kim,et al.  Nanoparticles with Precise Ratiometric Co‐Loading and Co‐Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer , 2014, Advanced functional materials.

[13]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[14]  Yuan Zhang,et al.  Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Lin Mei,et al.  The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment. , 2014, Biomaterials.

[16]  W. Mesker,et al.  Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts , 2014, Oncogene.

[17]  H. Yeger,et al.  TGF-β1 induces EMT reprogramming of porcine bladder urothelial cells into collagen producing fibroblasts-like cells in a Smad2/Smad3-dependent manner , 2013, Journal of Cell Communication and Signaling.

[18]  Huan Meng,et al.  Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. , 2013, ACS nano.

[19]  Yuhua Wang,et al.  Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. , 2013, ACS nano.

[20]  Lu Zhang,et al.  Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  R. Swann,et al.  Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.

[22]  I. Endo,et al.  Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells , 2013, Cancer science.

[23]  Shyh-Dar Li,et al.  Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. , 2013, Cancer research.

[24]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[25]  Y. Ba,et al.  Transforming growth factor-1 promotes the transcriptional activation of plasminogen activator inhibitor type 1 in carcinoma-associated fibroblasts. , 2012, Molecular medicine reports.

[26]  J. Bussink,et al.  Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy , 2012, Clinical Cancer Research.

[27]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[28]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[29]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[30]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[31]  P. Cirri,et al.  Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression , 2011, Cancer and Metastasis Reviews.

[32]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[33]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[34]  S. Denmeade,et al.  Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin , 2009, Molecular Cancer Therapeutics.

[35]  Xia Zhang,et al.  The expression of exogenous genes in macrophages: obstacles and opportunities. , 2009, Methods in molecular biology.

[36]  Y. Sung,et al.  Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. , 2008, Cancer research.

[37]  R. Weissleder,et al.  Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide , 2008, Molecular Cancer Therapeutics.

[38]  Leaf Huang,et al.  An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[39]  G. Giaccone,et al.  TRAIL therapy in non–small cell lung cancer cells: sensitization to death receptor–mediated apoptosis by proteasome inhibitor bortezomib , 2007, Molecular Cancer Therapeutics.

[40]  Kazunori Kataoka,et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling , 2007, Proceedings of the National Academy of Sciences.

[41]  A. Albini,et al.  TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells , 2006, British Journal of Cancer.

[42]  Won-Kyung Cho,et al.  Adeno‐associated virus‐mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model , 2006, The journal of gene medicine.

[43]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[44]  Jacques Buffle,et al.  Size effects on diffusion processes within agarose gels. , 2004, Biophysical journal.

[45]  R. Weissleder,et al.  Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. , 2004, Cancer research.

[46]  D. Lauffenburger,et al.  Self-organization of polarized cell signaling via autocrine circuits: computational model analysis. , 2004, Biophysical journal.

[47]  H. Kalthoff,et al.  FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. , 2001, Journal of cell science.

[48]  S. Batra,et al.  Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  R K Jain,et al.  Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.

[50]  K. Heider,et al.  Polycation‐based DNA complexes for tumor‐targeted gene delivery in vivo , 1999, The journal of gene medicine.